Global genomic and RNA profiles for novel risk stratification of neuroblastoma

Cancer Science

Volumn 101, Issue 11, 2010, Pages 2295-2301

  Ohira, Miki ^a,b   Nakagawara, Akira ^a  

^a Division of Biochemistry   (Japan)

^b CHIBA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; DNA; MICRORNA; RNA; TUMOR MARKER;

CANCER STAGING; CHILD; CLINICAL STUDY; COMPARATIVE GENOMIC HYBRIDIZATION; CPG ISLAND; CYTOGENETICS; DNA MICROARRAY; EPIGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMICS; HETEROZYGOSITY LOSS; HUMAN; METHYLATION; MOLECULAR GENETICS; MULTIVARIATE ANALYSIS; NEUROBLASTOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK MANAGEMENT; SURVIVAL RATE; UNIVARIATE ANALYSIS;

CHROMOSOME ABERRATIONS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MUTATION; NEUROBLASTOMA; PROTEIN-TYROSINE KINASES; RISK FACTORS;

EID: 78049415056     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01681.x     Document Type: Review

References (80)

1. Brodeur GM. Neuroblastoma: biological insight into a clinical enigma. Nat Rev Cancer 2003; 3: 203-16.
2. Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr 2005; 17: 7-13.
3. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984; 311: 231-5.
4. Schwab M, Alitalo K, Klempnauer KH et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983; 305: 245-8.
5. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224: 1121-4.
6. Bown N, Cotterill S, Lastowska M et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999; 340: 1954-61.
7. Attiyeh EF, London WB, Mosse YP et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005; 353: 2243-53.
8. Ohira M, Morohashi A, Inuzuka H et al. Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets. Oncogene 2003; 22: 5525-36.
9. Ohira M, Morohashi A, Nakamura Y et al. Neuroblastoma oligo-capping cDNA project: toward the understanding of the genesis and biology of neuroblastoma. Cancer Lett 2003; 197: 63-8.
10. Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 1992; 52: 1364-8.
11. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328: 847-54.
12. Nakagawara A, Milbrandt J, Muramatsu T et al. Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res 1995; 55: 1792-7.
13. Tanaka T, Slamon DJ, Shimoda H et al. Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis. Cancer Res 1988; 48: 1030-4.
14. Kawamoto T, Ohira M, Hamano S, Hori T, Nakagawara A. High expression of the novel endothelin-converting enzyme genes, Nbla03145/ECEL1alpha and beta, is associated with favorable prognosis in human neuroblastomas. Int J Oncol 2003; 22: 815-22.
15. Hamano S, Ohira M, Isogai E, Nakada K, Nakagawara A. Identification of novel human neuronal leucine-rich repeat (hNLRR) family genes and inverse association of expression of Nbla10449/hNLRR-1 and Nbla10677/hNLRR-3 with the prognosis of primary neuroblastomas. Int J Oncol 2004; 24: 1457-66.
16. Machida T, Fujita T, Oo ML et al. Increased expression of proapoptotic BMCC1, a novel gene with the BNIP2 and Cdc42GAP homology (BCH) domain, is associated with favorable prognosis in human neuroblastomas. Oncogene 2006; 25: 1931-42.
17. Li Y, Ozaki T, Kikuchi H, Yamamoto H, Ohira M, Nakagawara A. A novel HECT-type E3 ubiquitin protein ligase NEDL1 enhances the p53-mediated apoptotic cell death in its catalytic activity-independent manner. Oncogene 2008; 27: 3700-9.
18. Huang S, Laoukili J, Epping MT et al. ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell 2009; 15: 328-40.
19. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994; 14: 759-67.
20. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995; 1: 249-55.
21. Hossain MS, Ozaki T, Wang H et al. N-MYC promotes cell proliferation through a direct transactivation of neuronal leucine-rich repeat protein-1 (NLRR1) gene in neuroblastoma. Oncogene 2008; 27: 6075-82.
22. Aoyama M, Ozaki T, Inuzuka H et al. LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma. Cancer Res 2005; 65: 4587-97.
23. Islam A, Kageyama H, Takada N et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000; 19: 617-23.
24. Godfried MB, Veenstra M, V Sluis P et al. The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2. Oncogene 2002; 21: 2097-101.
25. Okabe-Kado J, Kasukabe T, Honma Y, Hanada R, Nakagawara A, Kaneko Y. Clinical significance of serum NM23-H1 protein in neuroblastoma. Cancer Sci 2005; 96: 653-60.
26. Saito-Ohara F, Imoto I, Inoue J et al. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 2003; 63: 1876-83.
27. Ando K, Ohira M, Ozaki T et al. Expression of TSLC1, a candidate tumorsuppressor gene mapped to chromosome 11q23, is downregulated in unfavorable neuroblastoma without promoter hypermethylation. Int J Cancer 2008; 123: 2087-94.
28. Nowacki S, Skowron M, Oberthuer A et al. Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma. Oncogene 2008; 27: 3329-38.
29. Berwanger B, Hartmann O, Bergmann E et al. Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell 2002; 2: 377-86.
30. Miyake I, Hakomori Y, Shinohara A et al. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 2002; 21: 5823-34.
31. Miyake I, Ohira M, Nakagawara A, Sakai R. Distinct role of ShcC dockingprotein in the differentiation of neuroblastoma. Oncogene 2009; 28: 662-73.
32. Terui E, Matsunaga T, Yoshida H et al. Shc family expression in neuroblastoma: high expression of shcC is associated with a poor prognosis in advanced neuroblastoma. Clin Cancer Res 2005; 11: 3280-7.
33. Boon K, Caron HN, Van Asperen R et al. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J 2001; 20: 1383-93.
34. Alaminos M, Mora J, Cheung NK et al. Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma. Cancer Res 2003; 63: 4538-46.
35. Evans AE, D'Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. Children's cancer study group A. Cancer 1971; 27: 374-8.
36. London WB, Castleberry RP, Matthay KK et al. Evidence for an age cutoff greater than 365-days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005; 23: 6459-65.
37. Brodeur GM, Pritchard J, Berthold F et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-77.
38. Shimada H, Ambros IM, Dehner LP et al. The International Neuroblastoma Pathology Classification the Shimada system. Cancer 1999; 86: 364-72.
39. Van't Veer LJ, Dai H, Van De Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6.
40. Wei JS, Greer BT, Westermann F et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 2004; 64: 6883-91.
41. Ohira M, Oba S, Nakamura Y et al. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 2005; 7: 337-50.
42. Oberthuer A, Berthold F, Warnat P et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006; 24: 5070-8.
43. Asgharzadeh S, Pique-Regi R, Sposto R et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 2006; 98: 1193-203.
44. Schramm A, Vandesompele J, Schulte JH et al. Translating expression profiling into a clinically feasible test to predict neuroblastoma outcome. Clin Cancer Res 2007; 13: 1459-65.
45. Chen QR, Song YK, Wei JS et al. An integrated cross-platform prognosis study on neuroblastoma patients. Genomics 2008; 92: 195-203.
46. Vermeulen J, De Preter K, Naranjo A et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009; 10: 663-71.
47. Mosse YP, Greshock J, Margolin A et al. High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. Genes Chromosomes Cancer 2005; 43: 390-403.
48. Wang Q, Diskin S, Rappaport E et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 2006; 66: 6050-62.
49. Tomioka N, Oba S, Ohira M et al. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Oncogene 2008; 27: 441-9.
50. Janoueix-Lerosey I, Schleiermacher G, Michels E et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009; 27: 1026-33.
51. Mosse YP, Laudenslager M, Longo L et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455: 930-5.
52. Chen Y, Takita J, Choi YL et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008; 455: 971-4.
53. Janoueix-Lerosey I, Lequin D, Brugieres L et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008; 455: 967-70.
54. George RE, Sanda T, Hanna M et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008; 455: 975-8.
55. Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 2005; 167: 213-22.
56. Rongshi L, Morris SW. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev 2008; 28: 372-412.
57. Amiel J, Laudier B, Attie-Bitach T et al. Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome. Nat Genet 2003; 33: 459-61.
58. Mosse YP, Laudenslager M, Khazi D et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet 2004; 75: 727-30.
59. Trochet D, Bourdeaut F, Janoueix-Lerosey I et al. Germline mutations of the paired-like homeobox 2B PHOX2B; gene in neuroblastoma. Am J Hum Genet 2004; 74: 761-4.
60. Maris JM, Mosse YP, Bradfield JP et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med 2008; 358: 2585-93.
61. Capasso M, Devoto M, Hou C et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet 2009; 41: 718-23.
62. Diskin SJ, Hou C, Glessner JT et al. CNV Copy number variation at 1q21.1 associated with neuroblastoma. Nature 2009; 459: 987-91.
63. Yang Q, Kiernan CM, Tian Y et al. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res 2007; 13: 3191-7.
64. Abe M, Ohira M, Kaneda A et al. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res 2005; 65: 828-34.
65. Abe M, Westermann F, Nakagawara A, Takato T, Schwab M, Ushijima T. Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. Cancer Lett 2007; 247: 253-8.
66. Abe M, Watanabe N, McDonell N et al. Identification of genes targeted by CpG island methylator phenotype in neuroblastomas, and their possible integrative involvement in poor prognosis. Oncology 2008; 74: 50-60.
67. Yagyu S, Gotoh T, Iehara T et al. Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma. Clin Cancer Res 2008; 14: 7011-19.
68. Misawa A, Tanaka S, Yagyu S et al. RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker. Br J Cancer 2009; 100: 399-404.
69. Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet 2006; 15: R17-19.
70. Prasanth KV, Spector DL. Eukaryotic regulatory RNAs: an answer to the 'genome complexity' conundrum. Genes Dev 2007; 21: 11-42.
71. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007; 26: 5017-22.
72. Cole KA, Attiyeh EF, Mosse YP et al. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res 2008; 6: 735-42.
73. Wei JS, Song YK, Durinck S et al. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008; 27: 5204-13.
74. Fontana L, Fiori ME, Albini S et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS ONE 2008; 3: e2236.
75. Ma L, Young J, Prabhala H et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12: 247-58.
76. Chen Y, Stallings RL. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 2007; 67: 976-83.
77. Schulte JH, Horn S, Otto T et al. MYCN regulates oncogenic microRNAs in neuroblastoma. Int J Cancer 2008; 122: 699-704.
78. Buckley PG, Alcock L, Bryan K et al. Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma. Clin Cancer Res 2010; 16: 2971-8.
79. Bray I, Bryan K, Prenter S et al. Widespread dysregulation of miRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS ONE 2009; 4: e7850.
80. Yu M, Ohira M, Li Y et al. High expression of ncRAN, a novel non-coding RNA mapped to chromosome 17q25.1, is associated with poor prognosis in neuroblastoma. Int J Oncol 2009; 34: 931-8.